SDZ 220-581 is used in life sciences as an orally bioavailable, competitive NMDA receptor antagonist (pKi 7.7). It dose-dependently protects male OF-l mice (18-26 g) against maximal electroshock seizures (MES) when administered orally at 3.2-32 mg/kg for 24 hours, with rapid onset and long duration of action.
